Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Eichhorst, Barbara
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Cramer P
,
von Tresckow J
,
Fink A-M
,
Robrecht S
,
Giza A
,
Tausch E
,
Müller L
,
Knauf W
,
Zingerle M
,
Al-Sawaf O
, et al.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol. 2024.
PubMed
Google Scholar
F
Eichhorst B
,
Niemann CU
,
Kater AP
,
Fürstenau M
,
von Tresckow J
,
Zhang C
,
Robrecht S
,
Gregor M
,
Juliusson G
,
Thornton P
, et al.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med. 2023;388(19):1739-1754.
PubMed
Google Scholar
I
Langerbeins P
,
Giza A
,
Robrecht S
,
Cramer P
,
von Tresckow J
,
Al-Sawaf O
,
Fink AMaria
,
Fürstenau M
,
Kater A
,
van der Spek E
, et al.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol. 2024.
PubMed
Google Scholar
P
Armand P
,
Murawski N
,
Molin D
,
Zain J
,
Eichhorst B
,
Gulbas Z
,
Hawkes EA
,
Pagel JM
,
Phillips T
,
Ribrag V
, et al.
Pembrolizumab in relapsed or refractory Richter syndrome.
Br J Haematol. 2020.
PubMed
Google Scholar
S
Fürstenau M
,
Giza A
,
Stumpf T
,
Robrecht S
,
Maurer C
,
Linde H
,
Jacobasch L
,
Dörfel S
,
Aldaoud A
,
von Tresckow J
, et al.
Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
Am J Hematol. 2021.
PubMed
Google Scholar
T
Al-Sawaf O
,
Ligtvoet R
,
Robrecht S
,
Stumpf J
,
Fink A-M
,
Tausch E
,
Schneider C
,
Boettcher S
,
Mikusko M
,
Ritgen M
, et al.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Nat Med. 2023.
PubMed
Google Scholar
von Tresckow J
,
Heyl N
,
Robrecht S
,
Giza A
,
Aldaoud A
,
Schlag R
,
Klausmann M
,
Linde H
,
Stein W
,
Schwarzer A
, et al.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol. 2023.
PubMed
Google Scholar